DEK oncogene is overexpressed during melanoma progression

被引:18
作者
Riveiro-Falkenbach, Erica [1 ]
Ruano, Yolanda [1 ]
Garcia-Martin, Rosa M. [1 ]
Lora, David [2 ]
Cifdaloz, Metehan [3 ]
Acquadro, Francesco [4 ]
Ballestin, Claudio [1 ]
Ortiz-Romero, Pablo L. [5 ]
Soengas, Maria S. [3 ]
Rodriguez-Peralto, Jose L. [1 ]
机构
[1] Univ Complutense, Hosp Univ Octubre 12, Dept Pathol, Med Sch,Inst I 12, Madrid, Spain
[2] Hosp Univ 12 Octubre, Inst I 12, Clin Res Unit CIBERESP, Madrid, Spain
[3] CNIO, Melanoma Lab, Madrid, Spain
[4] CNIO, Mol Cytogenet Grp, Madrid, Spain
[5] Univ Complutense, Sch Med, Hosp Univ Octubre 12, Dept Dermatol,Inst I 12, Madrid, Spain
关键词
CUTANEOUS MALIGNANT-MELANOMA; PREDICTS POOR-PROGNOSIS; HIGH EXPRESSION; BREAST-CANCER; ONCOPROTEIN; CHEMORESISTANCE; PROLIFERATION; PROTOONCOGENE; CARCINOMA; SURVIVAL;
D O I
10.1111/pcmr.12563
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
DEK is an oncoprotein involved in a variety of cellular functions, such as DNA repair, replication, and transcriptional control. DEK is preferentially expressed in actively proliferating and malignant cells, including melanoma cell lines in which DEK was previously demonstrated to play a critical role in proliferation and chemoresistance. Still, the impact of this protein in melanoma progression remains unclear. Thus, we performed a comprehensive analysis of DEK expression in different melanocytic tumors. The immunostaining results of 303 tumors demonstrated negligible DEK expression in benign lesions. Conversely, malignant lesions, particularly in metastatic cases, were largely positive for DEK expression, which was partially associated with genomic amplification. Importantly, DEK overexpression was correlated with histological features of aggressiveness in primary tumors and poor prognosis in melanoma patients. In conclusion, our study provides new insight into the involvement of DEK in melanoma progression, as well as proof of concept for its potential application as a marker and therapeutic target of melanoma.
引用
收藏
页码:194 / 202
页数:9
相关论文
共 39 条
[2]   DEK promotes HPV-positive and -negative head and neck cancer cell proliferation [J].
Adams, A. K. ;
Hallenbeck, G. E. ;
Casper, K. A. ;
Patil, Y. J. ;
Wilson, K. M. ;
Kimple, R. J. ;
Lambert, P. F. ;
Witte, D. P. ;
Xiao, W. ;
Gillison, M. L. ;
Wikenheiser-Brokamp, K. A. ;
Wise-Draper, T. M. ;
Wells, S. I. .
ONCOGENE, 2015, 34 (07) :868-877
[3]   Progression in cutaneous malignant melanoma is associated with distinct expression profiles -: A tissue microarray-based study [J].
Alonso, SR ;
Ortiz, P ;
Pollán, M ;
Pérez-Gómez, B ;
Sánchez, L ;
Acuña, MJ ;
Pajares, R ;
Martínez-Tello, FJ ;
Hortelano, CM ;
Piris, MA ;
Rodríguez-Peralto, JL .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :193-203
[4]  
BARNHILL RL, 1993, SEMIN DIAGN PATHOL, V10, P47
[5]   DEK expression is controlled by E2F and deregulated in diverse tumor types [J].
Carro, Maria Stella ;
Spiga, Fabio Mario ;
Quarto, Micaela ;
Di Ninni, Valentina ;
Volorio, Sara ;
Alcalay, Myriam ;
Muller, Heiko .
CELL CYCLE, 2006, 5 (11) :1202-1207
[6]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404
[7]   Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516
[8]  
DUBOW BE, 1990, MODERN PATHOL, V3, P734
[9]   Defining a 0.5-Mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction [J].
Evans, AJ ;
Gallie, BL ;
Jewett, MAS ;
Pond, GR ;
Vandezande, K ;
Underwood, J ;
Fradet, Y ;
Lim, G ;
Marrano, P ;
Zielenska, M ;
Squire, JA .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :285-293
[10]   Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma [J].
Grasemann, C ;
Gratias, S ;
Stephan, H ;
Schüler, A ;
Schramm, A ;
Klein-Hitpass, L ;
Rieder, H ;
Schneider, S ;
Kappes, F ;
Eggert, A ;
Lohmann, DR .
ONCOGENE, 2005, 24 (42) :6441-6449